O	0	6	Cyclin	Cyclin	NN	B-NP
O	7	9	D1	D1	NN	I-NP
O	9	10	/	/	SYM	B-NP
O	10	13	bcl	bcl	NN	I-NP
O	13	14	-	-	HYPH	B-NP
O	14	15	1	1	CD	I-NP
O	16	26	cooperates	cooperate	VBZ	B-VP
O	27	31	with	with	IN	B-PP
O	32	35	myc	myc	NN	B-NP
O	36	41	genes	gene	NNS	I-NP
O	42	44	in	in	IN	B-PP
O	45	48	the	the	DT	B-NP
O	49	59	generation	generation	NN	I-NP
O	60	62	of	of	IN	B-PP
B-Cancer	63	64	B	B	NN	B-NP
I-Cancer	64	65	-	-	HYPH	B-NP
I-Cancer	65	69	cell	cell	NN	I-NP
I-Cancer	70	78	lymphoma	lymphoma	NN	I-NP
O	79	81	in	in	IN	B-PP
O	82	92	transgenic	transgenic	JJ	B-NP
O	93	97	mice	mouse	NNS	I-NP
O	97	98	.	.	.	O

O	100	103	The	The	DT	B-NP
B-Cellular_component	104	115	chromosomal	chromosomal	JJ	I-NP
O	116	129	translocation	translocation	NN	I-NP
O	130	131	t	t	NN	I-NP
O	131	132	(	(	(	O
O	132	134	11	11	CD	B-NP
O	134	135	:	:	:	O
O	135	137	14	14	CD	B-NP
O	137	138	)	)	)	O
O	139	141	is	be	VBZ	B-VP
O	142	152	associated	associate	VBN	I-VP
O	153	157	with	with	IN	B-PP
O	158	163	human	human	JJ	B-NP
B-Cancer	164	172	lymphoid	lymphoid	JJ	I-NP
I-Cancer	173	182	neoplasia	neoplasia	NN	I-NP
O	183	192	affecting	affect	VBG	B-VP
B-Cell	193	204	centrocytic	centrocytic	JJ	B-NP
I-Cell	205	206	B	B	NN	I-NP
I-Cell	206	207	-	-	HYPH	O
I-Cell	207	212	cells	cell	NNS	B-NP
O	213	215	of	of	IN	B-PP
O	216	228	intermediate	intermediate	JJ	B-NP
O	229	244	differentiation	differentiation	NN	I-NP
O	244	245	.	.	.	O

O	246	248	As	As	IN	B-PP
O	249	250	a	a	DT	B-NP
O	251	262	consequence	consequence	NN	I-NP
O	263	266	the	the	DT	B-NP
O	267	273	cyclin	cyclin	NN	I-NP
O	274	276	D1	D1	NN	I-NP
O	277	278	(	(	(	O
O	278	281	bcl	bcl	NN	B-NP
O	281	282	-	-	HYPH	O
O	282	283	1	1	CD	O
O	283	284	)	)	)	O
O	285	289	gene	gene	NN	B-NP
O	290	292	is	be	VBZ	B-VP
O	293	303	juxtaposed	juxtapose	VBN	I-VP
O	304	306	to	to	TO	B-PP
O	307	310	the	the	DT	B-NP
O	311	325	immunoglobulin	immunoglobulin	NN	I-NP
O	326	331	heavy	heavy	JJ	I-NP
O	332	337	chain	chain	NN	I-NP
O	338	346	enhancer	enhancer	NN	I-NP
O	347	348	E	E	NN	I-NP
O	349	351	mu	mu	NN	I-NP
O	351	352	.	.	.	O

O	353	355	To	To	TO	B-VP
O	356	360	show	show	VB	I-VP
O	361	365	that	that	IN	B-SBAR
O	366	381	transcriptional	transcriptional	JJ	B-NP
O	382	392	activation	activation	NN	I-NP
O	393	395	of	of	IN	B-PP
O	396	402	cyclin	cyclin	NN	B-NP
O	403	405	D1	D1	NN	I-NP
O	406	408	is	be	VBZ	B-VP
O	409	417	causally	causally	RB	I-VP
O	418	426	involved	involve	VBN	I-VP
O	427	429	in	in	IN	B-PP
O	430	433	the	the	DT	B-NP
O	434	444	generation	generation	NN	I-NP
O	445	447	of	of	IN	B-PP
B-Cancer	448	449	B	B	NN	B-NP
I-Cancer	449	450	-	-	HYPH	B-NP
I-Cancer	450	454	cell	cell	NN	I-NP
I-Cancer	455	464	neoplasia	neoplasia	NN	I-NP
O	465	467	we	we	PRP	B-NP
O	468	472	have	have	VBP	B-VP
O	473	482	generated	generate	VBN	I-VP
O	483	493	transgenic	transgenic	JJ	B-NP
O	494	498	mice	mouse	NNS	I-NP
O	499	503	that	that	WDT	B-NP
O	504	509	carry	carry	VBP	B-VP
O	510	511	a	a	DT	B-NP
O	512	518	cyclin	cyclin	NN	I-NP
O	519	521	D1	D1	NN	I-NP
O	522	526	gene	gene	NN	I-NP
O	527	532	under	under	IN	B-PP
O	533	536	the	the	DT	B-NP
O	537	552	transcriptional	transcriptional	JJ	I-NP
O	553	560	control	control	NN	I-NP
O	561	563	of	of	IN	B-PP
O	564	567	the	the	DT	B-NP
O	568	569	E	E	NN	I-NP
O	570	572	mu	mu	NN	I-NP
O	573	580	element	element	NN	I-NP
O	580	581	.	.	.	O

O	582	583	E	E	NN	B-NP
O	584	586	mu	mu	NN	I-NP
O	587	593	cyclin	cyclin	NN	I-NP
O	594	596	D1	D1	NN	I-NP
O	597	607	transgenic	transgenic	JJ	I-NP
O	608	612	mice	mouse	NNS	I-NP
O	613	617	show	show	VBP	B-VP
O	618	622	only	only	RB	B-NP
O	623	627	very	very	RB	I-NP
O	628	634	subtle	subtle	JJ	I-NP
O	635	646	alterations	alteration	NNS	I-NP
O	647	649	in	in	IN	B-PP
O	650	653	the	the	DT	B-NP
O	654	661	cycling	cycling	NN	I-NP
O	662	671	behaviour	behaviour	NN	I-NP
O	672	674	of	of	IN	B-PP
B-Cell	675	676	B	B	NN	B-NP
I-Cell	676	677	-	-	HYPH	B-NP
I-Cell	677	681	cell	cell	NN	I-NP
I-Cell	682	693	populations	population	NNS	I-NP
O	694	696	in	in	IN	B-PP
O	697	700	the	the	DT	B-NP
B-Multi-tissue_structure	701	705	bone	bone	NN	I-NP
I-Multi-tissue_structure	706	712	marrow	marrow	NN	I-NP
O	713	721	compared	compare	VBN	B-PP
O	722	726	with	with	IN	B-PP
O	727	733	normal	normal	JJ	B-NP
O	734	738	mice	mouse	NNS	I-NP
O	739	742	and	and	CC	O
O	743	745	do	do	VBP	B-VP
O	746	749	not	not	RB	I-VP
O	750	757	develop	develop	VB	I-VP
B-Cancer	758	766	lymphoid	lymphoid	JJ	B-NP
I-Cancer	767	774	tumours	tumour	NNS	I-NP
O	774	775	.	.	.	O

O	776	783	However	However	RB	B-ADVP
O	783	784	,	,	,	O
O	785	786	E	E	NN	B-NP
O	787	789	mu	mu	SYM	B-NP
O	789	790	-	-	HYPH	B-VP
O	790	798	directed	direct	VBN	B-NP
O	799	811	coexpression	coexpression	NN	I-NP
O	812	814	of	of	IN	B-PP
O	815	821	cyclin	cyclin	NN	B-NP
O	822	824	D1	D1	NN	I-NP
O	825	828	and	and	CC	I-NP
O	829	830	N	N	NN	I-NP
O	830	831	-	-	HYPH	B-NP
O	831	834	MYC	MYC	NN	I-NP
O	835	837	or	or	CC	I-NP
O	838	839	L	L	NN	I-NP
O	839	840	-	-	HYPH	O
O	840	843	MYC	MYC	NN	B-NP
O	844	846	in	in	IN	B-PP
O	847	853	double	double	JJ	B-NP
O	854	864	transgenic	transgenic	JJ	I-NP
O	865	869	mice	mouse	NNS	I-NP
O	870	877	reveals	reveal	VBZ	B-VP
O	878	879	a	a	DT	B-NP
O	880	886	strong	strong	JJ	I-NP
O	887	898	cooperative	cooperative	JJ	I-NP
O	899	905	effect	effect	NN	I-NP
O	906	913	between	between	IN	B-PP
O	914	917	MYC	MYC	NN	B-NP
O	918	921	and	and	CC	I-NP
O	922	928	cyclin	cyclin	NN	I-NP
O	929	931	D1	D1	NN	I-NP
O	932	941	provoking	provoke	VBG	B-VP
O	942	945	the	the	DT	B-NP
O	946	951	rapid	rapid	JJ	I-NP
O	952	963	development	development	NN	I-NP
O	964	966	of	of	IN	B-PP
B-Cancer	967	973	clonal	clonal	JJ	B-NP
I-Cancer	974	977	pre	pre	AFX	I-NP
I-Cancer	977	978	-	-	HYPH	I-NP
I-Cancer	978	979	B	B	NN	I-NP
O	980	983	and	and	CC	I-NP
B-Cancer	984	985	B	B	NN	I-NP
I-Cancer	985	986	-	-	HYPH	B-NP
I-Cancer	986	990	cell	cell	NN	I-NP
I-Cancer	991	1000	lymphomas	lymphoma	NNS	I-NP
O	1000	1001	.	.	.	O

O	1002	1015	Interestingly	Interestingly	RB	B-ADVP
O	1015	1016	,	,	,	O
O	1017	1025	crossing	cross	VBG	B-VP
O	1026	1028	of	of	IN	B-PP
O	1029	1035	cyclin	cyclin	NN	B-NP
O	1036	1038	D1	D1	NN	I-NP
O	1039	1049	transgenic	transgenic	JJ	I-NP
O	1050	1054	mice	mouse	NNS	I-NP
O	1055	1059	with	with	IN	B-PP
O	1060	1061	E	E	NN	B-NP
O	1062	1064	mu	mu	SYM	B-NP
O	1065	1066	L	L	NN	I-NP
O	1066	1067	-	-	HYPH	B-NP
O	1067	1070	myc	myc	NN	I-NP
O	1071	1082	transgenics	transgenic	NNS	I-NP
O	1083	1087	that	that	WDT	B-NP
O	1088	1095	express	express	VBP	B-VP
O	1096	1101	their	their	PRP$	B-NP
O	1102	1111	transgene	transgene	NN	I-NP
O	1112	1114	in	in	IN	B-PP
O	1115	1119	both	both	CC	O
B-Cell	1120	1121	B	B	NN	B-NP
I-Cell	1121	1122	-	-	HYPH	I-NP
O	1123	1126	and	and	CC	I-NP
B-Cell	1127	1128	T	T	NN	I-NP
I-Cell	1128	1129	-	-	HYPH	I-NP
I-Cell	1129	1134	cells	cell	NNS	I-NP
O	1135	1138	but	but	CC	O
O	1139	1152	predominantly	predominantly	RB	B-VP
O	1153	1160	develop	develop	VBP	I-VP
B-Cancer	1161	1162	T	T	NN	B-NP
I-Cancer	1162	1163	-	-	HYPH	B-NP
I-Cancer	1163	1167	cell	cell	NN	I-NP
I-Cancer	1168	1175	tumours	tumour	NNS	I-NP
O	1176	1181	leads	lead	VBZ	B-VP
O	1182	1184	in	in	IN	B-PP
O	1185	1191	double	double	JJ	B-NP
O	1192	1203	transgenics	transgenic	NNS	I-NP
O	1204	1215	exclusively	exclusively	RB	B-ADVP
O	1216	1218	to	to	TO	B-PP
B-Cancer	1219	1220	B	B	NN	B-NP
I-Cancer	1220	1221	-	-	HYPH	B-NP
I-Cancer	1221	1225	cell	cell	NN	I-NP
I-Cancer	1226	1235	neoplasia	neoplasia	NN	I-NP
O	1235	1236	.	.	.	O

O	1237	1240	The	The	DT	B-NP
O	1241	1245	data	datum	NNS	I-NP
O	1246	1255	presented	present	VBN	B-VP
O	1256	1260	here	here	RB	B-ADVP
O	1261	1272	demonstrate	demonstrate	VBP	B-VP
O	1273	1277	that	that	IN	B-SBAR
O	1278	1293	transcriptional	transcriptional	JJ	B-NP
O	1294	1304	activation	activation	NN	I-NP
O	1305	1307	of	of	IN	B-PP
O	1308	1314	cyclin	cyclin	NN	B-NP
O	1315	1317	D1	D1	NN	I-NP
O	1318	1321	can	can	MD	B-VP
O	1322	1335	oncogenically	oncogenically	RB	I-VP
O	1336	1345	transform	transform	VB	I-VP
B-Cell	1346	1347	B	B	NN	B-NP
I-Cell	1347	1348	-	-	HYPH	O
I-Cell	1348	1353	cells	cell	NNS	B-NP
O	1354	1356	in	in	IN	B-PP
O	1357	1364	concert	concert	NN	B-NP
O	1365	1369	with	with	IN	B-PP
O	1370	1371	a	a	DT	B-NP
O	1372	1375	myc	myc	NN	I-NP
O	1376	1380	gene	gene	NN	I-NP
O	1380	1381	.	.	.	O

O	1382	1386	They	They	PRP	B-NP
O	1387	1396	establish	establish	VBP	B-VP
O	1397	1403	cyclin	cyclin	NN	B-NP
O	1404	1406	D1	D1	NN	I-NP
O	1407	1409	as	as	IN	B-PP
O	1410	1411	a	a	DT	B-NP
O	1412	1417	proto	proto	AFX	I-NP
O	1417	1418	-	-	HYPH	I-NP
O	1418	1426	oncogene	oncogene	NN	I-NP
O	1427	1432	whose	whose	WP$	B-NP
O	1433	1441	activity	activity	NN	I-NP
O	1442	1449	appears	appear	VBZ	B-VP
O	1450	1452	to	to	TO	I-VP
O	1453	1459	depend	depend	VB	I-VP
O	1460	1462	on	on	IN	B-PP
O	1463	1464	a	a	DT	B-NP
O	1465	1473	specific	specific	JJ	I-NP
B-Cell	1474	1478	cell	cell	NN	I-NP
O	1479	1483	type	type	NN	I-NP
O	1484	1486	as	as	RB	B-CONJP
O	1487	1491	well	well	RB	I-CONJP
O	1492	1494	as	as	IN	I-CONJP
O	1495	1497	on	on	IN	B-PP
O	1498	1499	a	a	DT	B-NP
O	1500	1508	specific	specific	JJ	I-NP
O	1509	1520	cooperating	cooperate	VBG	I-NP
O	1521	1528	partner	partner	NN	I-NP
O	1529	1532	and	and	CC	I-NP
O	1533	1537	link	link	NN	I-NP
O	1538	1550	disturbances	disturbance	NNS	I-NP
O	1551	1553	in	in	IN	B-PP
O	1554	1557	the	the	DT	B-NP
O	1558	1568	regulation	regulation	NN	I-NP
O	1569	1571	of	of	IN	B-PP
B-Cell	1572	1576	cell	cell	NN	B-NP
O	1577	1582	cycle	cycle	NN	I-NP
O	1583	1594	progression	progression	NN	I-NP
O	1595	1597	to	to	TO	B-PP
O	1598	1601	the	the	DT	B-NP
O	1602	1613	development	development	NN	I-NP
O	1614	1616	of	of	IN	B-PP
O	1617	1622	human	human	JJ	B-NP
B-Cancer	1623	1635	malignancies	malignancy	NNS	I-NP
O	1635	1636	.	.	.	O

